Revolution Medicines shares jumped to $134.80 Monday, up nearly 40%, after daraxonrasib delivered overall survival of 13.2 months in metastatic pancreatic ductal adenocarcinoma versus 6.7 months for chemotherapy in the Phase 3 RASolute 302 trial.
That’s the number PDAC researchers have been chasing for years. Pancreatic cancer carries a roughly 13% five-year survival rate across all detection stages, and treatments are scarce: mostly chemotherapy and surgery, both of which can be difficult for advanced tumors. RASolute 302 enrolled previously treated patients with metastatic PDAC. Results come from an interim analysis, but Revolution declared them final and said it’s moving to file with the FDA and other global regulatory agencies.
The filing won’t wait. Revolution received a Commissioner’s National Priority Voucher in October 2025, which compresses FDA review from the usual 10-12 months to just one or two. Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber and the trial’s principal investigator, called daraxonrasib “practice-changing for physicians.”
Daraxonrasib is an oral RAS(ON) multi-selective, non-covalent inhibitor targeting RAS mutations, the driver behind PDAC, non-small cell lung cancer, and colorectal cancer. Revolution has four Phase 3 trials underway for the drug, including a late-stage NSCLC trial and RASolute 303, which kicked off treatment in previously untreated metastatic PDAC patients earlier this month.
CEO Mark Goldsmith said the company is “moving with urgency” to complete global filings.
Sarah Chen